31 research outputs found
Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial
Full text linkBACKGROUND: Peripheral arterial disease is a progressive atherosclerotic disease with symptoms ranging from an intermittent claudication to acute critical limb ischemia and amputations. Drug-coated balloons and stents were developed to prevent neo-intimal proliferation and restenosis after percutaneous transluminal angioplasty. Randomized controlled trials showed that drug-coated, notably paclitaxel-coated, devices reduce restenosis, late lumen loss, and the need for target lesion re-vascularization compared with uncoated ones. However, the size of these trials was too small to prove superiority for "hard" clinical outcomes. Moreover, available studies were characterized by too restrictive eligibility criteria. Finally, it remains unclear whether paclitaxel-coated balloons may impair long-term survival. Alternative drug-coated balloons, the so-called limus-based analogs, have been approved for clinical use in patients with peripheral arterial disease. By encapsulating sirolimus in phospholipid drug nanocarriers, they optimize adhesion properties of sirolimus and provide better bioavailability.
METHODS: In this investigator-initiated all-comer open-label phase III randomized controlled trial, we will evaluate whether sirolimus-coated balloon angioplasty is non-inferior and eventually superior, according to a predefined hierarchical analysis, to uncoated balloon angioplasty in adults with infra-inguinal peripheral arterial disease requiring endovascular angioplasty. Key exclusion criteria are pregnancy or breastfeeding, known intolerance or allergy to sirolimus, and participation in a clinical trial during the previous 3āmonths. The primary efficacy outcome is the composite of two clinically relevant non-subjective "hard" outcomes: unplanned major amputation of the target limb and endovascular or surgical target lesion re-vascularization for critical limb ischemia occurring within 1āyear of randomization. The primary safety outcome includes death from all causes.
DISCUSSION: By focusing on clinically relevant outcomes, this study will provide useful information on the efficacy and safety of sirolimus-coated balloon catheters for infra-inguinal peripheral arterial disease in a representative ("all-comer") population of unselected patients. As regulatory agencies had raised safety concerns in patients exposed to paclitaxel-coated devices (versus uncoated ones), collect mortality data up to 5āyears after randomization will be collected
Social Bonding and Nurture Kinship: Compatibility between Cultural and Biological Approaches
Full text link
thorek1/MacroModelling.jl: v0.1.30
No full textMacroModelling v0.1.30
Diff since v0.1.29
Merged pull requests:
remove dash between url and citations (#52) (@jbytecode)
a single character update (#53) (@jbytecode)
Matrixequations (#54) (@thorek1)
update documenter (#55) (@thorek1
jfeist/QuantumAlgebra.jl: v1.3.0
No full textQuantumAlgebra v1.3.0
Diff since v1.2.0
Merged pull requests:
CompatHelper: add new compat entry for Preferences at version 1, (keep existing compat) (#17) (@github-actions[bot])
CompatHelper: bump compat for Latexify to 0.16, (keep existing compat) (#18) (@github-actions[bot])
Migrate from SnoopPrecompile to PrecompileTools (#19) (@timholy
